Euro
USD
British Pound
NULL
Product Description
KRIBIOLISA™ Ranibizumab (LUCENTIS) ELISA | KBI1029 | KRISHGEN BioSystems
The Ranibizumab (Lucentis) kit is an assay intended for the quantitative determination of Ranibizumab (Lucentis) in serum, plasma and cell culture samples.
Key features:
- Uses highly specific monoclonal anti-idiotypic antibodies
- Calibrators used is commerically available daratumumab injection itself
- Recovery: 80-120%
- Precision CV <15%
This Ranibizumab ELISA is for determination of Ranibizumab in human serum, plasma and cell culture supernatant.
Assay Background:
Ranibizumab is a humanized monoclonal antibody Fab, derived from the same mouse parent as Bevacizumab. Due to it`s anti-angiogenic properties, Ranibizumab is used for the treatment of a wet type of age related macular degeneration (a type of age-related vision loss). Sold under the trade name Lucentis, Ranibizumab inhibits angiogenesis by inhibiting VEGF-A. This is a mechanism similar to Bevacizumab.
Assay Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Ranibizumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Ranibizumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Ranibizumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Ranibizumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
